An interdepartmental Coordination Council for the Development of Domestic Pharmaceutical Innovations has been established in Russia. Its purpose is to launch systemic support for the full-cycle creation of innovative medicinal products based on proprietary development lines. This ranges from identifying biomolecular targets to market entry, with specific goals set for 2030 and 2036.
The council`s formation is a result of a five-party agreement signed after the St. Petersburg International Economic Forum. The signatories include the Ministry of Health, the Ministry of Industry and Trade, the Ministry of Education and Science of Russia, the company «Innopraktika», and the ANO «Innovative Engineering Center».
The parties have agreed on joint efforts to build a national portfolio of promising pharmaceutical innovations. These will be geared towards meeting domestic market demands and facilitating exports to friendly countries.
Deputy Minister of Health Sergey Glagolev stated that within the agreement`s framework, «promising areas of fundamental and applied research will be analyzed, and the prospects for studying biomolecular targets and developing new medicinal products in demand by the healthcare system will be assessed.»
At its inaugural meeting, the interdepartmental Coordination Council approved the work plan for 2025. The outcomes of the joint efforts will be presented at the «National Healthcare – 2025» forum.
Nikolay Kolpakov, General Director of the «Innovative Engineering Center», announced that the Federal Medical-Biological Agency, the Russian Academy of Sciences, the state corporation VEB.RF, the Russian Science Foundation, along with other development institutions, expert organizations, scientific institutions, and universities, are planned to be invited to participate in the council`s work.
Deputy Minister of Science and Higher Education Denis Sekirinsky noted that «to achieve the set goals within the agreement between the Ministry of Education and Science, the Ministry of Health, and the corporate research centers of domestic pharmaceutical companies, a research agenda will be coordinated and synchronized for analyzing, forecasting, and monitoring the demand for innovative medicines in the Russian Federation.»
Natalya Popova, First Deputy General Director of «Innopraktika», expressed confidence that a comprehensive approach to industry development will enable domestic innovative pharmaceutical products to increase their market share in national government procurement of original medicines by 2030 and sustain this growth moving forward.
Deputy Head of the Ministry of Industry and Trade, Ekaterina Priyezzheva, highlighted that «signing this agreement is a significant step in strengthening cooperation between the state, science, and industry for the creation of innovative domestic medicines. Joint work, utilizing `horizon scanning` tools and combining the best competencies of the participants, will allow us to create our own world-class innovations.»
